These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 12210733)

  • 1. Constitutive activation of met kinase in non-small-cell lung carcinomas correlates with anchorage-independent cell survival.
    Qiao H; Hung W; Tremblay E; Wojcik J; Gui J; Ho J; Klassen J; Campling B; Elliott B
    J Cell Biochem; 2002; 86(4):665-77. PubMed ID: 12210733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
    Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
    Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High expression of Met/hepatocyte growth factor receptor suppresses tumorigenicity in NCI-H1264 lung carcinoma cells.
    To C; Seiden I; Liu N; Wigle D; Tsao MS
    Exp Cell Res; 2002 Feb; 273(1):45-53. PubMed ID: 11795945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increase in hepatocyte growth factor receptor tyrosine kinase activity in renal carcinoma cells is associated with increased motility partly through phosphoinositide 3-kinase activation.
    Nakamura T; Kanda S; Yamamoto K; Kohno T; Maeda K; Matsuyama T; Kanetake H
    Oncogene; 2001 Nov; 20(52):7610-23. PubMed ID: 11753639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
    Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
    Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a hepatocyte growth factor autocrine loop in a murine mammary carcinoma.
    Rahimi N; Tremblay E; McAdam L; Park M; Schwall R; Elliott B
    Cell Growth Differ; 1996 Feb; 7(2):263-70. PubMed ID: 8822210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma.
    Tokunou M; Niki T; Eguchi K; Iba S; Tsuda H; Yamada T; Matsuno Y; Kondo H; Saitoh Y; Imamura H; Hirohashi S
    Am J Pathol; 2001 Apr; 158(4):1451-63. PubMed ID: 11290563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells.
    Song L; Turkson J; Karras JG; Jove R; Haura EB
    Oncogene; 2003 Jul; 22(27):4150-65. PubMed ID: 12833138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma.
    Qian CN; Guo X; Cao B; Kort EJ; Lee CC; Chen J; Wang LM; Mai WY; Min HQ; Hong MH; Vande Woude GF; Resau JH; Teh BT
    Cancer Res; 2002 Jan; 62(2):589-96. PubMed ID: 11809714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma.
    Tsai MF; Wang CC; Chang GC; Chen CY; Chen HY; Cheng CL; Yang YP; Wu CY; Shih FY; Liu CC; Lin HP; Jou YS; Lin SC; Lin CW; Chen WJ; Chan WK; Chen JJ; Yang PC
    J Natl Cancer Inst; 2006 Jun; 98(12):825-38. PubMed ID: 16788156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
    Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
    Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy.
    Stabile LP; Lyker JS; Huang L; Siegfried JM
    Gene Ther; 2004 Feb; 11(3):325-35. PubMed ID: 14737093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E1AF/PEA3 activates the Rho/Rho-associated kinase pathway to increase the malignancy potential of non-small-cell lung cancer cells.
    Hakuma N; Kinoshita I; Shimizu Y; Yamazaki K; Yoshida K; Nishimura M; Dosaka-Akita H
    Cancer Res; 2005 Dec; 65(23):10776-82. PubMed ID: 16322223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients.
    Vicent S; Garayoa M; López-Picazo JM; Lozano MD; Toledo G; Thunnissen FB; Manzano RG; Montuenga LM
    Clin Cancer Res; 2004 Jun; 10(11):3639-49. PubMed ID: 15173070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MAP kinase and beta-catenin signaling in HGF induced RPE migration.
    Liou GI; Matragoon S; Samuel S; Behzadian MA; Tsai NT; Gu X; Roon P; Hunt DM; Hunt RC; Caldwell RB; Marcus DM
    Mol Vis; 2002 Dec; 8():483-93. PubMed ID: 12500177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-8/CXCL8 is a growth factor for human lung cancer cells.
    Zhu YM; Webster SJ; Flower D; Woll PJ
    Br J Cancer; 2004 Nov; 91(11):1970-6. PubMed ID: 15545974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [c-Met and HGF expression in non-small-cell lung carcinomas].
    Korobko IV; Zinov'eva MV; Allakhverdiev AK; Zborovskaia IB; Svwrdlov ED
    Mol Gen Mikrobiol Virusol; 2007; (2):18-21. PubMed ID: 17598453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
    Ma PC; Kijima T; Maulik G; Fox EA; Sattler M; Griffin JD; Johnson BE; Salgia R
    Cancer Res; 2003 Oct; 63(19):6272-81. PubMed ID: 14559814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.
    Sutterlüty H; Mayer CE; Setinek U; Attems J; Ovtcharov S; Mikula M; Mikulits W; Micksche M; Berger W
    Mol Cancer Res; 2007 May; 5(5):509-20. PubMed ID: 17510316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.